SS Innovations International Inc. (NASDAQ: SSII) has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026, signaling the company's intensified focus on global commercialization and regulatory milestones. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
Romano joins SS Innovations after serving as CFO at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet. Her expertise is expected to support SS Innovations as it navigates the capital-intensive process of bringing the SSi Mantra to market in the United States and other regions. The company has been actively preparing for FDA review, as noted in its recent announcements (https://nnw.fm/yY4UM).
The leadership addition coincides with the company's recent graduation of the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program. SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment. This training initiative is critical to the adoption of the SSi Mantra system, as proficiency among surgeons is a key driver of robotic surgery utilization.
SS Innovations International (NASDAQ: SSII) develops innovative surgical robotic technologies aimed at making minimally invasive surgery more accessible globally. With Romano's appointment, the company gains a seasoned executive who can provide strategic financial oversight as it scales operations and pursues regulatory approvals. The global surgical robotics market is expected to grow significantly, and SS Innovations aims to capture a share by offering a cost-effective alternative to established systems.
The company has not yet provided a timeline for FDA submission or approval, but the ongoing international expansion and training programs indicate progress. Investors and industry observers will monitor how the new CFO's experience in capital markets and medtech finance helps SS Innovations secure the resources needed to compete in the rapidly evolving robotic surgery landscape.
